Clinical data show liraglutide does not increase heart risks and might even reduce them, leading Novo Nordisk officials to think the firm's diabetes drug will overcome regulatory hurdles that have plagued rival treatments, including Takeda's alogliptin. An FDA panel is set April 2 to evaluate whether liraglutide complies with the agency's new safety guidelines on the cardiovascular effects of diabetes medicines.

Full Story:

Related Summaries